Researchers Discover How to Overcome Drug Resistance in Deadliest Cancers With Few Available Targeted Therapies
Study Also Finds Biomarkers That Could Predict a Patient’s Response
Mount Sinai researchers have discovered a new drug combination that could provide the first targeted therapy for some of the deadliest cancers, as well as molecular predictors of tumor response to the therapy, according to a study published in Cell Reports in January.
Certain of these deadly cancers, including triple-negative breast cancer as well as pancreatic, lung, and colorectal cancers, occur when normally occurring proteins, including those called KRAS or BRAF, in the cells mutate and cause tumors. These tumors are responsive to small-molecule drugs called RAF and MEK inhibitors; however, drug resistance limits the effectiveness of these therapies. The Mount Sinai researchers found that adding another small molecule, called an SHP2 inhibitor, can prevent drug resistance in many patients with these tumors. The newly discovered drug combination would strengthen the effect of the RAF and MEK inhibitors by slowing, and potentially stopping, the cancer’s ability to build up resistance to the drugs.
“Our findings provide a blueprint for the clinical development of this potentially powerful treatment strategy for a large portion of patients with triple-negative breast cancer or other tumors that that are driven by mutated proteins like KRAS and BRAF,” said the study’s lead author, Poulikos I. Poulikakos, PhD, Assistant Professor of Oncological Sciences at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
The study also identified biomarkers that could predict a patient’s response to the combination therapy, providing a roadmap for the translation of this strategy to the clinic. Scientists made the discoveries by integrating biochemical studies with preclinical assessment of the drug combination using cancer tumor cell lines and tumors engrafted in mice.
The study was funded by the Dermatology Foundation, the Melanoma Research Foundation, the Melanoma Research Alliance, the Sidney Kimmel Foundation for Cancer Research, a Tisch Cancer Institute developmental award, a Breast Cancer Research Foundation grant, a 2017 Robin Chemers Neustein Postdoctoral Fellowship award and by the National Cancer Institute (R01CA204314 and T32CA078207).
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.